In a Phase 2 study, encaleret showed promising results for post-surgical hypoparathyroidism patients, with 80% achieving normal blood and urine calcium levels within 5 days of treatment initiation compared to 0% with conventional therapy. BridgeBio plans to start a clinical study for chronic hypoparathyroidism in 2026. The drug was well-tolerated with no serious adverse events reported. Encaleret works on the calcium-sensing receptor in the kidney, offering a potential pill-based solution for balancing calcium levels. Other studies presented at ASBMR 2025 showed infigratinib’s positive effects on bone growth in mouse models of skeletal conditions.

Read more at GlobeNewswire: Encaleret Showed Parathyroid Hormone-Independent